Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in T-Cell Large Granular Lymphocytic Leukemia
NCT05592015Phase 2Recruiting
- Start
- May 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in T-cell large granular lymphocytic leukemia. Started May 2023; status: recruiting.
02
Drugs
03
Conditions
T-cell large granular lymphocytic leukemia
Beyond the preview
Go deeper on NCT05592015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592015.